Trial Profile
A phase I dose-escalation trial of CSTD 002 NK cells infused before and after haploidentical HSCT for patients with high-risk acute myeloid leukaemia (AML), myelodysplastic syndromes (MDS) or chronic myeloid leukaemia (CML)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Oct 2018
Price :
$35
*
At a glance
- Drugs K NK002 (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- 12 Oct 2018 New trial record
- 23 Aug 2018 Results published in the Blood